Health‐related quality of life in reduced‐intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: <scp>BMT CTN</scp> 1102
Rachel Cusatis(Medical College of Wisconsin), Kathryn E. Flynn(Medical College of Wisconsin), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Corey Cutler(Harvard University), Stephanie J. Lee(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Bronwen E. Shaw(Royal Marsden NHS Foundation Trust), Anita D’Souza, Betty K. Hamilton(Cleveland Clinic), Wael Saber(Medical College of Wisconsin), Ryotaro Nakamura(City Of Hope National Medical Center), Michael J. Martens(Medical College of Wisconsin), Mary M. Horowitz(Medical College of Wisconsin), Alyssa D. Gregory(National Institutes of Health)
Cited by 19
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
|Journal of Clinical Oncology|2006|2k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k